Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
GSK, Vanderbilt Team For Obesity Drug
by Lisa M. Jarvis
February 18, 2013
| A version of this story appeared in
Volume 91, Issue 7
GlaxoSmithKline and Vanderbilt University will work together to develop drugs to treat severe obesity. Led by biologist Roger Cone, Vanderbilt scientists have discovered positive allosteric modulators of melanocortin-4 receptor (MC4-R), a protein involved in body weight regulation. In exchange for access to the MC4-R modulators, GSK will provide Vanderbilt with three years of research support as well as milestone payments on any drug candidates developed. The partners hope to have an MC4-R modulator in Phase I studies by 2016.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter